Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Envafolimab |
| Trade Name | |
| Synonyms | KN035 |
| Drug Descriptions |
Envafolimab (KN035) is a nanobody that targets PD-L1 (CD274) and prevents interaction with PD-1 (PDCD1), potentially resulting in decreased tumor growth (PMID: 28280600). |
| DrugClasses | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| CAS Registry Number | 2102192-68-5 |
| NCIT ID | C129714 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Doxorubicin + Envafolimab + YH001 | Doxorubicin Envafolimab YH001 | 0 | 1 |
| Envafolimab | Envafolimab | 0 | 2 |
| Envafolimab + Fluorouracil + Leucovorin + Oxaliplatin | Envafolimab Fluorouracil Leucovorin Oxaliplatin | 0 | 0 |
| Envafolimab + Ipilimumab | Envafolimab Ipilimumab | 0 | 1 |
| Envafolimab + YH001 | Envafolimab YH001 | 0 | 1 |